Hubei Biocause Pharmaceutical Co., Ltd. (SHE:000627)
2.740
0.00 (0.00%)
Apr 30, 2025, 3:04 PM CST
SHE:000627 Revenue
Hubei Biocause Pharmaceutical had revenue of 4.54B CNY in the quarter ending September 30, 2024, a decrease of -41.47%. This brings the company's revenue in the last twelve months to 40.70B, down -22.90% year-over-year. In the year 2023, Hubei Biocause Pharmaceutical had annual revenue of 48.28B, down -2.10%.
Revenue (ttm)
40.70B
Revenue Growth
-22.90%
P/S Ratio
0.33
Revenue / Employee
23.06M
Employees
1,765
Market Cap
13.54B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 48.28B | -1.03B | -2.10% |
Jan 1, 2023 | 49.31B | 614.72M | 1.26% |
Jan 1, 2022 | 48.70B | 7.57B | 18.40% |
Dec 31, 2020 | 41.13B | -8.54B | -17.20% |
Dec 31, 2019 | 49.67B | 19.79B | 66.25% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
China Merchants Bank | 295.79B |
Ping An Insurance (Group) Company of China | 945.67B |
Industrial Bank | 151.04B |
Shanghai Pudong Development Bank | 101.05B |
CITIC Securities Company | 64.88B |
East Money Information | 12.50B |
China Pacific Insurance (Group) | 315.25B |
Guotai Haitong Securities | 45.79B |